ReviewJournal of clinical tuberculosis and other mycobacterial diseases2026
Multidrug-resistant tuberculosis (MDR-TB) in people living with HIV: Clinical issues, therapeutic challenges and perspectives in sub-Saharan Africa. A narrative review.
Review in Journal of clinical tuberculosis and other mycobacterial diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV coinfection and multidrug-resistant tuberculosis (MDR-TB) pose a major public health challenge in sub-Saharan Africa, where high HIV prevalence promotes tuberculosis progression and complicates its management. In people living with HIV (PLHIV), profound immunosuppression leads to atypical clinical presentations, low bacillary load, and increased diagnostic difficulty. Despite advances such as the introduction of the GeneXpert test and all-oral treatments such as the BPaL regimen, access to these tools remains uneven, exacerbating diagnostic delays and mortality. Drug interactions between antiretrovirals and second-line antituberculosis drugs, as well as the toxicity of prolonged regimens, further complicate clinical management. Mortality among coinfected patients remains high, sometimes exceeding 40%, particularly in the absence of early diagnosis and adequate treatment. Improved early detection, integration of HIV/MDR-TB care and accessibility to innovative treatments are essential to change the trajectory of this dual epidemic in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.